Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws i...(target _new http://www.anesiva.com and ...)

Date:6/30/2008

target="_new">http://www.anesiva.com and going to the Investor Information page. A slide presentation that will accompany the call also will be available for download from the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: (706) 645-9291) and giving the following pass code: 53907567.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue
'/>"/>

SOURCE Anesiva, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation